Enveric Historical Balance Sheet

ENVB Stock

USD 0.33 0.01 2.94%

Trend analysis of Enveric Biosciences balance sheet accounts such as Total Current Liabilities of 3.7 M or Total Stockholder Equity of 1.9 M provides information on Enveric Biosciences' total assets, liabilities, and equity, which is the actual value of Enveric Biosciences to its prevalent stockholders. By breaking down trends over time using Enveric Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Enveric Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enveric Biosciences is a good buy for the upcoming year.

Enveric Biosciences Inventory

(17,100)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.

About Enveric Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Enveric Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Enveric Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Enveric Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Enveric currently owns. An asset can also be divided into two categories, current and non-current.

Enveric Biosciences Balance Sheet Chart

At present, Enveric Biosciences' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 3.7 M, whereas Total Assets are forecasted to decline to about 4.1 M.

Total Assets Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Enveric Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Enveric Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Enveric Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Enveric Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Enveric Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Enveric Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.At present, Enveric Biosciences' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 3.7 M, whereas Total Assets are forecasted to decline to about 4.1 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	1.2M	3.4M	1.1M	1.9M
Total Assets	26.7M	19.6M	4.3M	4.1M

Other Current Liab Total Assets

Enveric Biosciences balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Short Term Debt	Common Stock	Current Deferred Revenue	Common Stock Total Equity
Total Assets		0.81	0.89	0.85	-0.03	0.04	0.32	0.72	0.33	0.88	0.0	0.33	0.47	-0.18	0.56	-0.21	0.35	-0.12	0.92	0.79	0.81	0.54	0.63	0.35	-0.65	0.09
Other Current Liab	0.81		0.94	0.58	-0.13	0.22	0.31	0.78	0.11	0.79	0.18	0.11	0.49	-0.14	0.2	-0.14	0.28	-0.16	0.83	0.53	0.61	0.57	0.56	0.14	-0.4	0.12
Total Current Liabilities	0.89	0.94		0.6	-0.23	0.37	0.37	0.87	0.0	0.89	0.11	0.0	0.61	-0.21	0.45	-0.17	0.27	-0.21	0.94	0.53	0.69	0.66	0.71	0.21	-0.49	0.18
Total Stockholder Equity	0.85	0.58	0.6		0.3	-0.44	0.02	0.35	0.71	0.59	-0.29	0.71	0.11	-0.02	0.3	-0.19	0.46	0.2	0.59	0.92	0.64	0.21	0.39	0.38	-0.72	-0.09
Property Plant And Equipment Net	-0.03	-0.13	-0.23	0.3		-0.8	-0.74	-0.54	0.74	-0.42	-0.56	0.74	-0.8	0.85	-0.33	-0.01	0.55	0.8	-0.28	0.47	-0.41	-0.56	-0.47	-0.3	-0.41	-0.4
Net Debt	0.04	0.22	0.37	-0.44	-0.8		0.51	0.6	-0.91	0.41	0.44	-0.91	0.69	-0.43	0.39	0.0	-0.33	-0.59	0.39	-0.53	0.21	0.55	0.47	0.0	0.25	0.34
Retained Earnings	0.32	0.31	0.37	0.02	-0.74	0.51		0.41	-0.34	0.46	0.35	-0.33	0.63	-0.82	0.43	0.31	-0.31	-0.97	0.48	-0.04	0.46	0.62	0.51	0.33	0.22	0.48
Accounts Payable	0.72	0.78	0.87	0.35	-0.54	0.6	0.41		-0.31	0.94	0.48	-0.31	0.82	-0.43	0.54	-0.31	-0.08	-0.32	0.86	0.21	0.77	0.66	0.65	0.19	-0.22	0.17
Cash	0.33	0.11	0.0	0.71	0.74	-0.91	-0.34	-0.31		-0.08	-0.41	1.0	-0.48	0.32	-0.15	-0.1	0.43	0.48	-0.01	0.82	0.08	-0.27	-0.22	0.12	-0.44	-0.3
Non Current Assets Total	0.88	0.79	0.89	0.59	-0.42	0.41	0.46	0.94	-0.08		0.35	-0.08	0.76	-0.43	0.62	-0.24	0.03	-0.32	0.93	0.43	0.91	0.64	0.68	0.34	-0.38	0.19
Non Currrent Assets Other	0.0	0.18	0.11	-0.29	-0.56	0.44	0.35	0.48	-0.41	0.35		-0.41	0.49	-0.47	0.2	-0.25	-0.65	-0.41	0.21	-0.32	0.39	0.26	-0.13	-0.06	0.55	0.01
Cash And Short Term Investments	0.33	0.11	0.0	0.71	0.74	-0.91	-0.33	-0.31	1.0	-0.08	-0.41		-0.48	0.32	-0.15	-0.1	0.43	0.48	-0.01	0.82	0.08	-0.27	-0.22	0.12	-0.44	-0.3
Net Receivables	0.47	0.49	0.61	0.11	-0.8	0.69	0.63	0.82	-0.48	0.76	0.49	-0.48		-0.68	0.51	-0.36	-0.11	-0.6	0.65	-0.04	0.67	0.76	0.77	0.26	-0.1	0.19
Common Stock Shares Outstanding	-0.18	-0.14	-0.21	-0.02	0.85	-0.43	-0.82	-0.43	0.32	-0.43	-0.47	0.32	-0.68		-0.34	-0.13	0.57	0.82	-0.28	0.14	-0.52	-0.48	-0.4	-0.46	-0.38	-0.45
Non Current Liabilities Total	0.56	0.2	0.45	0.3	-0.33	0.39	0.43	0.54	-0.15	0.62	0.2	-0.15	0.51	-0.34		-0.17	-0.03	-0.35	0.65	0.25	0.57	0.58	0.5	0.08	-0.28	0.02
Inventory	-0.21	-0.14	-0.17	-0.19	-0.01	0.0	0.31	-0.31	-0.1	-0.24	-0.25	-0.1	-0.36	-0.13	-0.17		-0.3	-0.34	-0.19	-0.2	-0.31	-0.24	-0.21	0.12	0.39	0.67
Other Current Assets	0.35	0.28	0.27	0.46	0.55	-0.33	-0.31	-0.08	0.43	0.03	-0.65	0.43	-0.11	0.57	-0.03	-0.3		0.42	0.19	0.52	-0.07	0.18	0.41	-0.17	-0.87	-0.4
Other Stockholder Equity	-0.12	-0.16	-0.21	0.2	0.8	-0.59	-0.97	-0.32	0.48	-0.32	-0.41	0.48	-0.6	0.82	-0.35	-0.34	0.42		-0.33	0.25	-0.31	-0.56	-0.41	-0.25	-0.39	-0.5
Total Liab	0.92	0.83	0.94	0.59	-0.28	0.39	0.48	0.86	-0.01	0.93	0.21	-0.01	0.65	-0.28	0.65	-0.19	0.19	-0.33		0.54	0.79	0.68	0.69	0.27	-0.48	0.2
Total Current Assets	0.79	0.53	0.53	0.92	0.47	-0.53	-0.04	0.21	0.82	0.43	-0.32	0.82	-0.04	0.14	0.25	-0.2	0.52	0.25	0.54		0.46	0.17	0.25	0.26	-0.68	-0.13
Intangible Assets	0.81	0.61	0.69	0.64	-0.41	0.21	0.46	0.77	0.08	0.91	0.39	0.08	0.67	-0.52	0.57	-0.31	-0.07	-0.31	0.79	0.46		0.54	0.53	0.54	-0.31	0.13
Short Long Term Debt Total	0.54	0.57	0.66	0.21	-0.56	0.55	0.62	0.66	-0.27	0.64	0.26	-0.27	0.76	-0.48	0.58	-0.24	0.18	-0.56	0.68	0.17	0.54		0.79	0.21	-0.21	0.15
Short Term Debt	0.63	0.56	0.71	0.39	-0.47	0.47	0.51	0.65	-0.22	0.68	-0.13	-0.22	0.77	-0.4	0.5	-0.21	0.41	-0.41	0.69	0.25	0.53	0.79		0.27	-0.56	0.16
Common Stock	0.35	0.14	0.21	0.38	-0.3	0.0	0.33	0.19	0.12	0.34	-0.06	0.12	0.26	-0.46	0.08	0.12	-0.17	-0.25	0.27	0.26	0.54	0.21	0.27		-0.04	0.63
Current Deferred Revenue	-0.65	-0.4	-0.49	-0.72	-0.41	0.25	0.22	-0.22	-0.44	-0.38	0.55	-0.44	-0.1	-0.38	-0.28	0.39	-0.87	-0.39	-0.48	-0.68	-0.31	-0.21	-0.56	-0.04		0.34
Common Stock Total Equity	0.09	0.12	0.18	-0.09	-0.4	0.34	0.48	0.17	-0.3	0.19	0.01	-0.3	0.19	-0.45	0.02	0.67	-0.4	-0.5	0.2	-0.13	0.13	0.15	0.16	0.63	0.34

Click cells to compare fundamentals

Enveric Biosciences Account Relationship Matchups

Enveric Biosciences balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.0M	4.1M	26.7M	19.6M	4.3M	4.1M
Other Current Liab	4.8M	681.3K	1.2M	3.4M	1.1M	1.9M
Total Current Liabilities	14.4M	681.3K	2.1M	4.0M	2.3M	3.7M
Total Stockholder Equity	10.6M	3.4M	22.3M	14.7M	2.0M	1.9M
Net Debt	4.4M	(1.6M)	(17.2M)	(17.7M)	(2.3M)	(2.2M)
Retained Earnings	(40.5M)	(11.8M)	(60.7M)	(79.2M)	(96.5M)	(91.7M)
Accounts Payable	4.7M	681.3K	683.4K	463.3K	1.2M	1.3M
Cash	431.4K	1.6M	17.4M	17.7M	2.3M	2.3M
Non Current Assets Total	17.4M	1.8M	9.0M	1.1M	718.3K	682.4K
Cash And Short Term Investments	431.4K	1.6M	17.4M	17.7M	2.3M	2.4M
Net Receivables	8.8M	7.9M	6.4M	224.6K	258.3K	245.4K
Common Stock Shares Outstanding	26.4K	115.1K	472.3K	1.4M	2.2M	2.3M
Liabilities And Stockholders Equity	25.0M	4.1M	26.7M	19.6M	4.3M	4.1M
Non Current Liabilities Total	2.4M	4.2M	9.6M	0.0	2.3M	527.1K
Other Current Assets	783.6K	1.4M	761.7K	1.3M	1.1M	1.1M
Other Stockholder Equity	51.0M	15.2M	82.7M	94.4M	99.0M	103.9M
Total Liab	14.4M	681.3K	4.4M	4.0M	2.3M	2.2M
Total Current Assets	7.6M	2.3M	17.7M	18.4M	3.6M	4.2M
Intangible Assets	3.6M	1.8M	6.9M	379.7K	210.9K	200.4K
Common Stock	25.2K	101.0K	325.8K	20.8K	27.4K	26.0K
Accumulated Other Comprehensive Income	60.0K	(181.3K)	(30.8K)	(536.7K)	(569.7K)	(598.2K)
Net Tangible Assets	(65.5K)	(1.8M)	1.6M	13.8M	15.9M	16.7M
Net Invested Capital	15.5M	3.4M	22.3M	14.7M	2.0M	1.9M
Net Working Capital	(6.8M)	1.6M	15.7M	14.4M	1.2M	909.9K
Capital Stock	29.5K	133.7K	325.8K	20.8K	27.4K	26.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:

How To Invest In Enveric

Details

Is Enveric Stock a good investment?

Details

What is Enveric Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.42)

Revenue Per Share

37.678

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.81)

Return On Equity

(2.06)

The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enveric Historical Balance Sheet

Enveric Biosciences Inventory

(17,100)

About Enveric Balance Sheet Analysis

Enveric Biosciences Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Enveric Biosciences balance sheet Correlations

Enveric Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Enveric Biosciences balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Liabilities	+ 0.94	Other Current Liab
Total Liab	+ 0.94	Total Current Liabilities
Non Current Assets Total	+ 0.94	Accounts Payable
Total Liab	+ 0.93	Non Current Assets Total
Total Liab	+ 0.92	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.91	Net Debt
Cash	- 0.91	Net Debt
Current Deferred Revenue	- 0.87	Other Current Assets
Common Stock Shares Outstanding	- 0.82	Retained Earnings
Net Receivables	- 0.8	Property Plant And Equipment Net